PM greets Jayalalithaa on 65th birthday

CHENNAI: Prime Minister Manmohan Singh on Sunday greeted Tamil Nadu chief minister J Jayalalithaa on her 65th birthday.

A statement issued by the state government here said the prime minister greeted Jayalalithaa over the phone on her birthday.

Tamil Nadu governor K Rosaiah, leader of opposition in the Lok Sabha Sushma Swaraj of the BJP, Communist Party of India national secretary D Raja, many MPs, members of the Tamil Nadu assembly, industrialists and others also greeted Jayalalithaa.

At the AIADMK party headquarters here, senior leaders, state ministers and others were present when a cake weighing 65 kg was cut and distributed.

Across the state, AIADMK leaders and cadres celebrated Jayalalithaa's birthday. The chief minister is also the general secretary of the AIADMK.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Crash at Daytona Exposes Risks to Fans












The risks of racing extend beyond the drivers.



Fans can wind up in the danger zone, too.



A horrifying crash on the last lap of a race at Daytona International Speedway injured at least 30 fans Saturday and provided another stark reminder of what can happen when a car going nearly 200 mph is suddenly launched toward the spectator areas.



The victims were sprayed with large chunks of debris — including a tire — after rookie Kyle Larson's machine careened into the fencing that is designed to protect the massive grandstands lining NASCAR's most famous track.



"I love the sport," said Shannan Devine, who witnessed the carnage from her 19th-row seat, about 250 feet away. "But no one wants to get hurt over it."



The fencing served its primary purpose, catapulting what was left of Larson's car back onto the track. But it didn't keep potentially lethal shards from flying into the stands.



"There was absolute shock," Devine said. "People were saying, 'I can't believe it, I can't believe it. I've never seen this happen, I've never seen this happen. Did the car through the fence?' It was just shock and awe. Grown men were reaching out and grabbing someone, saying, 'Oh my gosh! Oh my gosh!' It was just disbelief, absolute disbelief."



From Daytona to Le Mans to a rural road in Ireland, auto racing spectators have long been too close to the action when parts start flying. The crash in the second-tier Nationwide race follows a long list of accidents that have left fans dead or injured.





The most tragic incident occurred during the 1955 24 Hours of Le Mans, when two cars collided near the main stands. The wreck sent debris hurtling into the crowd, while one of the cars flipped upside down and exploded in a giant fireball.



Eighty-three spectators and driver Pierre Levegh were killed, and 120 fans were injured.



The Daytona crash began as the field approached the checkered flag and leader Regan Smith attempted to block Brad Keselowski. That triggered a chain reaction, and rookie Kyle Larson hit the cars in front of him and went airborne into the fence.



The entire front end was sheared off Larson's car, and his burning engine wedged through a gaping hole in the fence. Chunks of debris from the car were thrown into the stands, including a tire that cleared the top of the fence and landed midway up the spectator section closest to the track.



"I thought the car went through the fence," Devine said. "I didn't know if there was a car on top of people. I didn't know what to think. I'm an emotional person. I immediately started to cry. It was very scary, absolutely scary. I love the speed of the sport. But it's so dangerous."



The fencing used to protect seating areas and prevent cars from hurtling out of tracks has long been part of the debate over how to improve safety.



Three-time Indianapolis 500 winner Dario Franchitti lost close friend Dan Wheldon at Las Vegas in the 2011 IndyCar season finale, when Wheldon's car catapulted into the fencing and his head struck a support post. Since his death, IndyCar drivers have called for studies on how to improve the safety barriers.



Franchitti renewed the pleas on Twitter after the Daytona crash, writing "it's time (at)Indycar (at)nascar other sanctioning bodies & promoters work on an alternative to catch fencing. There has to be a better solution."



Another fan who witnessed the crash said he's long worried that sizable gaps in the fencing increase the chances of debris getting through to the stands.





Read More..

Maldivain ex-leader exits Indian embassy: New Delhi






NEW DELHI: Former Maldives president Mohamed Nasheed left the Indian embassy in the capital Male on Saturday, an Indian official said, 10 days after he sought refuge in the mission in a bid to avoid arrest.

Nasheed's exit came after a Maldivian court earlier this week postponed his trial for abuse of power when he was in office and India sent an envoy to the nation of 330,000 Sunni Muslims to try and end the political standoff.

"He (Nasheed) entered India's mission on February 13th of his own volition and decided to leave on his own," Indian foreign ministry spokesman Syed Akbaruddin said in New Delhi.

Nasheed, 45, is accused of abusing his powers after he won the first free elections in 2008 in the Indian Ocean holiday destination. The pro-democracy campaigner was ousted last year following a mutiny by police and troops.

"He is not planning to go back (to the embassy). He has ended seeking refuge there," Nasheed's Maldivian Democratic Party spokeswoman Shauna Aminath told AFP.

Nasheed, a famed global warming activist, has condemned the charges of abuse of power against him as a "politically motivated sham".

The Maldivian court postponed the hearing scheduled for last Wednesday after police said they were unable to arrest the former president and bring him before the magistrate, according to Nasheed's party.

Presidential spokesman Masood Imad had confirmed the hearing had been cancelled but said that the case was still pending.

Nasheed's taking refuge at the Indian embassy in Male had strained relations between India and its tiny neighbour.

The Maldivian foreign ministry last weekend summoned Indian High Commissioner (ambassador) D.M. Mulay and accused India of allowing Nasheed to use its embassy for political activities.

India had appealed to its neighbour to guarantee "the integrity of the electoral process" before the presidential election set for September, but had strongly denied interfering in politics in the Maldives.

-AFP/fl



Read More..

Won't tolerate any tampering with Ram Setu: BJP

NEW DELHI: BJP today warned the government against going ahead with the Sethusamudram project, saying the sentiments of crores of Hindus are attached to the issue and it will not tolerate any tampering with the Ram Setu.

"We would like to warn the government on the Ram Setu issue. It is ignoring the recommendations of the R K Pachauri Committee report and going ahead with the project. This is an issue related to Hindu sentiments and beliefs," party spokesperson Ravi Shankar Prasad told reporters here.

The principal opposition party demanded scrapping of the project.

The Pachauri Committee, which submitted its report to the Supreme Court, has said the Sethusamudram shipping channel project is not viable on economic and ecological grounds.

Government has rejected the report and maintained that it intends to pursue the project which will cut through the Adam's Bridge, popularly known as Ram Setu.

"BJP and the nation will not tolerate any tampering with the Ram Setu. Why is cutting through it the only solution?" Prasad asked.

Asked about the government's contention that over Rs 800 crore has already been spent on the project, the BJP leader said it is not a question of what amount was spent but why this expenditure was incurred in the first place.

"Without the Ram Setu you cannot think of the Ramayana," Prasad said, adding that sentiments of crores of Hindu are attached to the issue.

Ram Setu is the mythical bridge on which Lord Ram and his army crossed the sea to invade Ravan's kingdom.

BJP has always been opposed to the Sethusamudram project which envisages dredging of a shipping channel, proposed to be 30 m wide, 12 m deep and 167 km long, across the Palk Straits between India and Sri Lanka.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..

Cyberattacks Bring Attention to Security Reform











Recent accusations of a large-scale cyber crime effort by the Chinese government left many wondering what immediate steps the president and Congress are taking to prevent these attacks from happening again.


On Wednesday, the White House released the administration's Strategy on Mitigating the Theft of U.S. Trade Secrets as a follow-up to the president's executive order. The strategy did not outwardly mention China, but it implied U.S. government awareness of the problem.


"We are taking a whole of government approach to stop the theft of trade secrets by foreign competitors or foreign governments by any means -- cyber or otherwise," U.S. Intellectual Property Enforcement Coordinator Victoria Espinel said in a White House statement.


As of now, the administration's strategy is the first direct step in addressing cybersecurity, but in order for change to happen Congress needs to be involved. So far, the Cyber Intelligence Sharing and Protection Act (CISPA) is the most notable Congressional legislation addressing the problem, despite its past controversy.


Last April, CISPA was introduced by House Intelligence Committee Chairman Mike Rogers, R-Mich., and Rep. Dutch Ruppersberger, D-Md. The act would allow private companies with consumer information to voluntarily share those details with the NSA and the DOD in order to combat cyber attacks.






Peter Parks/AFP/Getty Images







The companies would be protected from any liabilities if the information was somehow mishandled. This portion of the act sounded alarm bells for CISPA's opponents, like the ACLU, which worried that this provision would incentivize companies to share individuals' information with disregard.


CISPA passed in the House of Representatives, despite a veto threat from the White House stemming from similar privacy concerns. The bill then died in the Senate.


This year, CISPA was reintroduced the day after the State of the Union address during which the president declared an executive order targeting similar security concerns from a government standpoint.


In contrast to CISPA, the executive order would be initiated on the end of the government, and federal agencies would share relevant information regarding threats with private industries, rather than asking businesses to supply data details. All information shared by the government would be unclassified.


At the core of both the executive order and CISPA, U.S. businesses and the government would be encouraged to work together to combat cyber threats. However, each option would clearly take a different route to collaboration. The difference seems minimal, but has been the subject of legislative debates between the president and Congress for almost a year, until now.


"My response to the president's executive order is very positive," Ruppersberger told ABC News. "[The president] brought up how important information sharing is [and] by addressing critical infrastructure, he took care of another hurdle that we do not have to deal with."


Addressing privacy roadblocks, CISPA backers said the sharing of private customer information with the government, as long as personal details are stripped, is not unprecedented.


"Think of what we do with HIPAA in the medical professions; [doctors do not need to know] the individual person, just the symptoms to diagnose a disease," Michigan Gov. John Engler testified at a House Intelligence Committee hearing in an attempt to put the problem into context.






Read More..

Iran appears to advance in construction of Arak nuclear plant


VIENNA (Reuters) - Iran appears to be advancing in its construction of a research reactor Western experts say could offer the Islamic state a second way of producing material for a nuclear bomb, if it decided to embark on such a course, a U.N. report showed.


Iran has almost completed installation of cooling and moderator circuit piping in the heavy water plant near the town of Arak, the International Atomic Energy Agency (IAEA) said in a confidential report issued to member states late on Thursday.


Nuclear analysts say this type of reactor could yield plutonium for nuclear arms if the spent fuel is reprocessed, something Iran has said it has no intention of doing. Iran has said it "does not have reprocessing activities", the IAEA said.


In its previous report on Iran, in November, the Vienna-based U.N. agency said installation work at Arak was continuing, without giving any indication of how far advanced it was.


Iran rejects Western allegations it seeks to develop a capability to assemble nuclear weapons, saying its atomic program is entirely peaceful and that the Arak reactor will produce isotopes for medical and agricultural use.


Iran says it plans to begin operating the facility in the first quarter of 2014, the IAEA said. Tehran last year postponed the planned start-up from the third quarter of 2013, a target that Western experts said always had seemed unrealistic.


The Arms Control Association, a Washington-based research and advocacy group, said late last year that it was questionable whether Iran would be able to meet the new target date as well, in view of "significant delays and impeded access to necessary materials" because of international sanctions imposed on Iran.


Western worries about Iran are focused largely on uranium enrichment plants at Natanz and Fordow, as such material refined to a high level can provide the fissile core of an atomic bomb. But experts say Arak may also be a proliferation issue.


The Arak facility is a "growing source of concern", said Mark Fitzpatrick, director of the non-proliferation and disarmament program of the International Institute for Strategic Studies (IISS), a London-based think-tank.


Israel, believed to be the Middle East's only nuclear-armed state, sees Iran's nuclear program as a serious danger and has threatened to attack its atomic sites if diplomacy and sanctions fail to resolve the decade-old dispute.


If it does, the nuclear sites at Natanz, Fordow and Arak in central Iran are likely to be targets. Fitzpatrick said it could be Arak that triggers a conflict because attacking it after it is launched could cause an environmental disaster.


TESTING FUEL FOR ARAK REACTOR


Thursday's quarterly IAEA report showed Iran expanding its uranium enrichment program in defiance of tightening Western sanctions, installing advanced centrifuge machines at its main enrichment plant near the town of Natanz.


The report, issued just a few days before six world powers and Iran are due to resume negotiations after an eight-month hiatus, underlined the tough task facing the West in seeking to pressure Tehran to curb its nuclear activities.


Cliff Kupchan, Middle East director at the Eurasia consultancy, said Iran had adopted a defiant policy of pressing ahead with its nuclear program, despite harsh sanctions.


"As a result, Israel and the U.S. Congress will press a receptive U.S. administration to move forward with new and even harsher sanctions," he said in a research note.


Enriched uranium can fuel nuclear power plants, Iran's stated aim, but also provide the explosive core of a nuclear weapon if refined much further. Making plutonium from spent fuel is a second way of obtaining potential bomb material.


The Institute for Science and International Security (ISIS), a U.S. think-tank, noted that Iran planned to use a medical research reactor in Tehran, known as TRR, to test fuel for Arak.


"The TRR is now more than a medical isotope production reactor, Iran's stated use for the reactor, and is necessary for the operation" of Arak, it said in a report.


If operated optimally, the heavy-water plant could produce about nine kilograms (20 pounds) of plutonium a year, or enough for about two nuclear bombs annually, ISIS has said previously.


"Before it could use any of the plutonium in a nuclear weapon, however, it would first have to separate the plutonium from the irradiated fuel," it added on its website.


Iran has repeatedly declared it has no plans to reprocess the spent fuel. But, "similarly sized reactors ostensibly built for research" have been used by India, Israel, North Korea and Pakistan to make plutonium for weapons, Fitzpatrick said.


(Editing by Mark Heinrich)



Read More..

ECB says banks to repay US$80.5b in ultra-cheap loans






FRANKFURT: The European Central Bank said on Friday that 356 eurozone banks will repay early 61.1 billion euros ($80.5 billion) of a second batch of ultra-cheap three-year loans made available to them a year ago in emergency liquidity measures.

Under the ECB's special long-term refinancing operations or LTROs, which it launched to avert a looming credit crunch in the single currency area, banks had the option of repaying any part of the money after just one year.

"Accordingly, on February 27 ... 61.1 billion will be repaid in the tender by 356 counter parties," the ECB said in a short statement.

The LTROs, injections of liquidity into the banking system with ultra-long maturities of three years, were launched in two batches -- 468 billion euros in December 2011 and 529 billion euros in February 2012.

At the time, they were widely credited with pulling Europe back from the brink of a dangerous credit crunch.

Both rounds of LTRO included provisions to allow early repayment after one year, if banks so chose, with the first repayment window opening on January 30, and the second on February 27. After that, repayments can continue on a weekly basis, depending on demand.

At the first repayment of the first batch on January 30, 278 banks repaid 137 billion euros.

- AFP/al



Read More..

Two gets life term in Saccha Khera gangrape and suicide case

ROTHAK: Five months after the rape and suicide case of a minor girl in Saccha Khera village of Jind district evoked outrage across the state and the Congress chief Sonia Gandhi also visited the family to assure speedy justice, a Jind district court sentenced the two accused to life imprisonment on Friday.

The trial against fifth accused, who is a minor, is pending in a juvenile court while two other accused including a woman who were facing conspiracy charges were acquitted in the case. According to information, the additional district and sessions judge RN Bharti had convicted two youths - Pradeep Kumar and Sandeep Kumar- guilty in the case on February 18 and announced the jail term today.

The police had booked five persons identified as Pradeep, 24, his brother Manoj, 28, Manoj's wife Meena, 25, Sandeep, 24, and another minor youth on the charges of gangrape and abatement to suicide of the minor girl in the same village. The victim as well as all the accused belong to scheduled caste. The prosecution stated that the girl was gangraped by two neighbouring youths - Pradeep and minor accused, on October 6 while three other accused had helped them in the crime. On getting out of the clutches of the accused, the victim rushed to her house and set herself ablaze and suffered about 80 % burn injuries.

She recorded her statement in the Jind civil hospital in front of the magistrate and was later referred to the PGIMS at Rohtak in critical condition.

The victim succumbed to the burn injuries at Rohtak the same day. The ADJ however had acquitted Manoj and his wife Meena in the case for lack of evidence. Three days after the incident, the Congress president Sonia Gandhi accompanied by Haryana chief minister Bhupinder Singh Hooda visited the family of victim and assured that justice would be done to them and the accused would be brought to book soon. With a spate of rape cases being reported across the state, Gandhi's visit put the state government under pressure to act swiftly after which series of steps were taken for ensuring safety of women.

Read More..